RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Hubei Minkang Pharmaceutical Stock

Hubei Minkang Pharmaceutical P/S 2024

Hubei Minkang Pharmaceutical P/S

0

Ticker

HBMK

ISIN

US44352W1018

As of Nov 19, 2024, Hubei Minkang Pharmaceutical's P/S ratio stood at 0, a -100% change from the 2.39 P/S ratio recorded in the previous year.

The Hubei Minkang Pharmaceutical P/S history

Hubei Minkang Pharmaceutical Aktienanalyse

What does Hubei Minkang Pharmaceutical do?

Hubei Minkang Pharmaceutical Ltd is a Chinese pharmaceutical company that was founded in 1988. Since its establishment, the company has specialized in the development, production, and sale of medicines, particularly traditional Chinese medicines. The company is based in Xianning City, Hubei Province, and employs over 1,000 staff, including over 400 technicians and researchers. It is a leading manufacturer of medicines in China and has a good reputation in the national and international markets. Hubei Minkang Pharmaceutical has a wide business model that specializes in the development and marketing of medicines in various areas. These include: - Traditional Chinese Medicine: Traditional Chinese Medicine (TCM) is one of the company's specialties. TCM is a holistic approach that focuses on the body's natural healing powers. It involves the use of plants, minerals, and animal products to treat diseases and ailments. The company develops and produces a variety of TCM products that are highly valued by Chinese society. - State-of-the-Art Medicines: The company has also invested in modern medicines in recent years and has a specialized research and development department to develop these products. The portfolio also includes impressive developments in cancer therapy and treatment options for cardiovascular diseases. - Veterinary Medicine: Hubei Minkang Pharmaceutical Ltd also produces a wide range of products used in veterinary medicine. This includes remedies for parasites, antibiotics, and vitamins. - Research and Development: The company has established itself as an innovation driver through investment in the research and development of medicines. Hubei Minkang Pharmaceutical Ltd has been awarded with high-quality assurance and boasts a modern production facility that is standardized at the international level. The company has also received certifications from global institutions such as Good Manufacturing Practice (GMP). This ensures that all products are of the highest quality, safety, and efficacy. The company is committed to achieving its self-set corporate goals in a sustainable manner, thus creating a sense of shared responsibility towards the environment and society. Overall, Hubei Minkang Pharmaceutical Ltd is a company that focuses on the development, production, and sale of medicines, particularly traditional Chinese medicine. It has established itself as a successful player in the national and international markets through its specialized divisions and modern manufacturing processes. Hubei Minkang Pharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/S Details

Decoding Hubei Minkang Pharmaceutical's P/S Ratio

Hubei Minkang Pharmaceutical's Price to Sales (P/S) Ratio is a crucial financial metric that measures the company's market valuation relative to its total sales revenue. It's calculated by dividing the company's market capitalization by its total sales over a specific period. A lower P/S ratio can indicate that the company is undervalued, while a higher ratio may suggest overvaluation.

Year-to-Year Comparison

Comparing Hubei Minkang Pharmaceutical's P/S ratio yearly provides insights into how the market perceives the company’s value relative to its sales. An increasing ratio over time can indicate growing investor confidence, while a decreasing trend might reflect concerns about the company’s revenue generation capabilities or market conditions.

Impact on Investments

The P/S ratio is instrumental for investors evaluating Hubei Minkang Pharmaceutical's stock. It offers insights into the company’s efficiency in generating sales and its market valuation. Investors use this ratio to compare similar companies within the same industry, aiding in selecting stocks that offer the best value for investment.

Interpreting P/S Ratio Fluctuations

Variations in Hubei Minkang Pharmaceutical’s P/S ratio can result from changes in the stock price, sales revenue, or both. Understanding these fluctuations is crucial for investors to evaluate the company’s current valuation and future growth potential, aligning their investment strategies accordingly.

Frequently Asked Questions about Hubei Minkang Pharmaceutical stock

What is the price-to-earnings ratio of Hubei Minkang Pharmaceutical?

The price-earnings ratio of Hubei Minkang Pharmaceutical is currently 0.

How has the price-earnings ratio of Hubei Minkang Pharmaceutical changed compared to last year?

The price-to-earnings ratio of Hubei Minkang Pharmaceutical has increased by -100% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Hubei Minkang Pharmaceutical high compared to other companies?

Yes, the price-to-earnings ratio of Hubei Minkang Pharmaceutical is high compared to other companies.

How does an increase in the price-earnings ratio of Hubei Minkang Pharmaceutical affect the company?

An increase in the price-earnings ratio of Hubei Minkang Pharmaceutical would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Hubei Minkang Pharmaceutical affect the company?

A decrease in the price-earnings ratio of Hubei Minkang Pharmaceutical would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Hubei Minkang Pharmaceutical?

Some factors that influence the price-earnings ratio of Hubei Minkang Pharmaceutical are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Hubei Minkang Pharmaceutical pay?

Over the past 12 months, Hubei Minkang Pharmaceutical paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Hubei Minkang Pharmaceutical is expected to pay a dividend of 0 USD.

What is the dividend yield of Hubei Minkang Pharmaceutical?

The current dividend yield of Hubei Minkang Pharmaceutical is .

When does Hubei Minkang Pharmaceutical pay dividends?

Hubei Minkang Pharmaceutical pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Hubei Minkang Pharmaceutical?

Hubei Minkang Pharmaceutical paid dividends every year for the past 0 years.

What is the dividend of Hubei Minkang Pharmaceutical?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Hubei Minkang Pharmaceutical located?

Hubei Minkang Pharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Hubei Minkang Pharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Hubei Minkang Pharmaceutical from 11/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did Hubei Minkang Pharmaceutical pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of Hubei Minkang Pharmaceutical in the year 2023?

In the year 2023, Hubei Minkang Pharmaceutical distributed 0 USD as dividends.

In which currency does Hubei Minkang Pharmaceutical pay out the dividend?

The dividends of Hubei Minkang Pharmaceutical are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Hubei Minkang Pharmaceutical

Our stock analysis for Hubei Minkang Pharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Hubei Minkang Pharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.